<DOC>
	<DOCNO>NCT01226108</DOCNO>
	<brief_summary>OBJECTIVES : Primary Objective The primary objective decrease inconvenience least 10 % least 50 % subject . Secondary Objectives The secondary objective : To evaluate patch improve tinnitus patient 's quality life sleep quality . METHODOLOGY Study Design : An open safety performance clinical investigation antinitus patch patient manifest tinnitus . Treatment Duration : 1 patch per day 3 week Primary Endpoint : Tinnitus severity questionnaire ( TSQ ) Performance Parameters : Tinnitus severity questionnaire ( TSQ ) numerical rating scale ( NRS ) measure tinnitus annoyance . Quality life sleep quality Safety Parameters : Adverse Reactions</brief_summary>
	<brief_title>The Akloma Tinnitus Patch Patients With Manifested Tinnitus</brief_title>
	<detailed_description />
	<mesh_term>Tinnitus</mesh_term>
	<criteria>Adults sex &gt; 18 year age Signed informed consent Patients suffer tinnitus ≥ 4 week study entry Manifested tinnitus grade II KlockhoffLindblom tinnitus severity grade scale . Tinnitus score 5 ( numerical rating scale tinnitus annoyance ) Pure tone average better 40 dB bad hearing ear . Pregnant lactate woman Malignancy serious medical condition Skin disease Simultaneous previous ( within 30 day prior study entry ) participation clinical study use experimental drug device . Severe psychiatric disorder Serious suicidal risk Patients start treatment make change treatment drug know influence tinnitus within 6 week study start . Patients untreated high blood pressure ≥140/90 mmHg Other tinnitus treatment within 6 week study entry . Previous use Antinitus patch Known allergy sensitivity compound Antinitus placebo patch .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>